<DOC>
	<DOCNO>NCT00414999</DOCNO>
	<brief_summary>The formation new blood vessel ( angiogenesis ) , blood vessel leakage , inflammation contribute progression eye disease , age-related macular degeneration ( AMD ) , lead cause irreversible , severe loss vision people 55 year age old develop world . TG100801 new drug inhibits ocular angiogenesis , vascular leak , inflammation laboratory study , may great utility treatment diseases AMD . The purpose study assess safety , ocular tolerability , blood pharmacokinetics TG100801 escalate dos healthy volunteer .</brief_summary>
	<brief_title>A Phase 1 Safety Study TG100801 Eye Drops Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<criteria>Male female healthy volunteer meet follow criterion eligible inclusion study . Subjects participate Part A study may participate Part B . Age &gt; 18 year ( 50 % subject must &gt; 40 year age ) . Corrected visual acuity &gt; 20/25 eye . Intraocular pressure ( IOP ) &lt; 21 mm Hg , difference eye &lt; 4 mm Hg . Ability tolerate selfadminister vehicle eye drop satisfaction study staff . Tolerance commercially available benzalkonium chloridepreserved , artificial tear solution one eye . Normal slit lamp exam dilate fundoscopic exam within 2 week dose . Normal clinical laboratory profile , define complete blood count , serum chemistry , urinalysis value within normal range . Willing abstain concomitant use ocular systemic medication ( exclude acetaminophen multivitamin ) 2 week prior start study dose study completion . Willing comply schedule visit , treatment plan , laboratory assessment , studyrelated procedure . Provide write informed consent participate . Subjects meet follow criterion exclude study : History ocular surgery , trauma , chronic ocular disease . Current use contact lenses discontinuation contact lens use within 2 week first dose day . Any ocular abnormality ocular symptom ( define nonzero score assessment scale ) . Use ocular agent ( include eye drop ) within past 2 month anticipate use ocular agent study period . Systemic corticosteroid use within past 6 month . History evidence ocular infection , inflammation , blepharitis , conjunctivitis 2 month ; history herpes simplex keratitis . Presence nonhealing wound , ulcer , fracture , medical condition associate bleeding . Use antimitotic antimetabolite therapy within 2 month enrollment . Loss , donation , removal 400 mL blood within past 2 month . Women pregnant breastfeeding , nonsterile premenopausal woman refuse use two proven method contraception least 2 week follow final dose study drug . Enrollment another investigational drug device study within 2 month study entry . Ongoing cardiac arrhythmias prolongation QTc interval &gt; 450 msec male &gt; 470 msec female . Known liver , kidney , cardiovascular , neurologic , pulmonary disease ; treat untreated hypertension ; current history drug alcohol abuse . Known human immunodeficiency virus acquire immunodeficiency syndromerelated illness . Known intolerance excipients study drug formulation . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , would affect subject 's ability follow studyrelated procedure , may interfere interpretation study result , investigator 's opinion , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Macular degeneration</keyword>
	<keyword>Vascular disease</keyword>
	<keyword>Retinal disorder</keyword>
	<keyword>Macular edema</keyword>
</DOC>